Medical monitoring

Assure Sets Monthly Record for Cash Collection and Procedures in June 2021

Retrieved on: 
Tuesday, July 6, 2021

DENVER, July 06, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced a monthly record for cash collection and number of procedures during June 2021.

Key Points: 
  • DENVER, July 06, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), announced a monthly record for cash collection and number of procedures during June 2021.
  • Results and expectations relating to billing and collections include:
    The Company collected a monthly record $2.7 million in June 2021.
  • Based upon recent discussions with various insurance providers, Assure expects to continue the strong trend of collections in 2021.
  • Farlinger concluded, The Company reported more than 1,600 cases in June 2021, our highest number of monthly procedures ever.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
Friday, July 2, 2021

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On July 1, 2021, Senseonics Compensation Committee granted 5 new non-executive employees non-qualified stock options to purchase an aggregate of 66,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Retrieved on: 
Thursday, July 1, 2021

"We greatly appreciate the thoughtful analysis and guidance provided by the Data Monitoring Committee following their review of the interim trial data.

Key Points: 
  • "We greatly appreciate the thoughtful analysis and guidance provided by the Data Monitoring Committee following their review of the interim trial data.
  • Consistent with our expectations, we are pleased with the DMC recommendation to continue this trial without modification.
  • This marks the third recommendation by the DMC supporting the continuation of the Mino-Lok trial.
  • With Covid-19 restrictions easing, we believe we are now better positioned to accelerate our efforts to complete the trial.

Vivalink Extends Medical Wearables Data Platform with Enhanced Temperature and Cardiac Monitors

Retrieved on: 
Wednesday, June 30, 2021

CAMPBELL, Calif., June 30, 2021 /PRNewswire/ -- Vivalink , a leading provider of connected healthcare solutions known for its unique medical wearable sensor data platform, today announces a newly enhanced temperature and cardiac electrocardiogram (ECG) monitor.

Key Points: 
  • CAMPBELL, Calif., June 30, 2021 /PRNewswire/ -- Vivalink , a leading provider of connected healthcare solutions known for its unique medical wearable sensor data platform, today announces a newly enhanced temperature and cardiac electrocardiogram (ECG) monitor.
  • Adopted by over 100 healthcare application partners and customers in 25 countries, the newly enhanced sensors are part of Vivalink's vitals data platform which consists of a broad range of medical wearable sensors, edge network technologies, and cloud data services.
  • Built for remote patient monitoring, virtual hospitals and decentralized clinical trials, the sensors are specifically designed for use in remote and ambulatory situations.
  • We leverage unique physiology-optimized medical wearable sensors and data services to enable a deeper and more clinical relationship between provider and patient.

Vector to Debut Remote Cardiac Program Maturity Assessment at Heart Rhythm 2021

Retrieved on: 
Wednesday, June 30, 2021

Vector will debut the assessment at the Heart Rhythm Societys annual conference, Heart Rhythm 2021 , which kicks off on June 30th virtually, and in Boston July 28th.

Key Points: 
  • Vector will debut the assessment at the Heart Rhythm Societys annual conference, Heart Rhythm 2021 , which kicks off on June 30th virtually, and in Boston July 28th.
  • Earlier in the year, Vector conducted the 2021 State of Remote Cardiac Monitoring Survey that generated important market information regarding the overall state of remote cardiac monitoring in the US.
  • As a result, Vector developed the RCM Maturity Assessment to help cardiac practices identify where they fall on the maturity curve and how to approach next steps in program advancement.
  • For those unable to attend the live Heart Rhythm 2021 event, the RCM Maturity Assessment is available on VectorRemote.com.

WHO and ECDC launch indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions

Retrieved on: 
Monday, June 28, 2021

Countries have readily employed innovative technologies throughout the COVID-19 pandemic to support the implementation of public health and social measures.

Key Points: 
  • Countries have readily employed innovative technologies throughout the COVID-19 pandemic to support the implementation of public health and social measures.
  • Digital proximity tracingusing smartphones or purpose-built devices to capture anonymized interactions between individuals then issuing alertsemerged during the pandemic as a new means of support to government-led programmes for contact tracing.
  • ECDC and WHO developed this indicator framework in consultation with public health experts globally.
  • The framework will provide countries with a standardized approach for evaluating their use of digital proximity tracing solutions.

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
Monday, June 28, 2021

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.
  • The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions in the US.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

WebCareHealth provides safe alternative to address national crisis on shortage of Blue Top Collection Tubes used to test coagulation

Retrieved on: 
Monday, June 28, 2021

CoagMgr from the WebCareHealth platform is a unique streamlined, web-based model for managing at-home INR (International Normalized Ratio) patients .

Key Points: 
  • CoagMgr from the WebCareHealth platform is a unique streamlined, web-based model for managing at-home INR (International Normalized Ratio) patients .
  • It is designed so health care providers can work directly with patients to more easily monitor and adjust dosages in real time.
  • "WebCareHealth recognizes the current need for urgent solutions and is committed to relieving this crisis by offering our safe in-home INR testing approach, CoagMgr .
  • Founded in 2014 WCH develops innovative cloud-based software solutions that enable healthcare providers to remotely monitor the health of patients managing chronic illnesses.

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

Retrieved on: 
Friday, June 25, 2021

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.

Key Points: 
  • DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.
  • Poster 77-LB, A Retrospective Analysis of the Association between HbA1c and Continuous Glucose Monitor Use for U.S.
  • For more information about the 81st Scientific Sessions of the American Diabetes Association and to register to virtually attend the conference, visit professional.diabetes.org/scientific-sessions .
  • DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.

Optimize Health Hires Lyft's Former Head of Fleet Service Operations as New SVP of Operations

Retrieved on: 
Thursday, June 24, 2021

Over the course of her 4+ year tenure at Lyft, Ajmera led the rollout of a number of new ventures for the ride-sharing leader, most recently as their Head of Fleet Service Operations.

Key Points: 
  • Over the course of her 4+ year tenure at Lyft, Ajmera led the rollout of a number of new ventures for the ride-sharing leader, most recently as their Head of Fleet Service Operations.
  • "We are thrilled to have Neha's experience building high-performing teams and scaling tech-enabled services as we build out our clinical operations," said Jeff LeBrun, CEO of Optimize Health.
  • I look forward to working with the Optimize Health team and our customers to do just that."
  • Optimize Health makes it easy for healthcare providers to offer patient-centric, reimbursable remote patient monitoring.